Skip to main content
    N

    Neurocrine Biosciences Inc (NBIX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $165.31
    -2.09 (-1.25%)

    Market Cap: $16.94B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Neurocrine Biosciences Inc (NBIX) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Neurocrine Biosciences (NBIX) to earn $10.59 per share in the fiscal year ending Dec 31, 2026, on revenue of $3.99B. Of 29 analysts, 25 rate the stock Buy or Strong Buy, 4 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 4 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 29 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 86% of the ratings.

    RatingAnalystsShare
    Strong Buy413.8%
    Buy2172.4%
    Hold413.8%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    29

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 16.1% and revenue estimates rise 14.8%.

    Fiscal year ending Dec 31, 2026
    $10.59
    EPS consensus, revenue $3.99B
    Fiscal year ending Dec 31, 2027
    $12.30
    EPS consensus, revenue $4.58B
    Next report
    Feb 9, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$10.59$9.35 to $12.3916$3.99B$3.91B to $4.18B23
    Dec 31, 2027$12.30$9.36 to $16.2216$4.58B$4.37B to $5.07B25

    Quarterly Estimates

    The EPS consensus rises from $2.02 for the quarter ending Dec 31, 2026 to $2.73 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$2.02$1.34 to $2.5629$1.11B$1.03B to $1.26B27
    Mar 31, 2027$2.73$2.32 to $3.116$1.07B$1.03B to $1.09B8

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 3 upward and 7 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202614
    Fiscal year ending Dec 31, 202722
    Quarter ending Mar 31, 202701

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 4.1% from $10.17.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$10.59$10.24$10.21$10.20$10.17+4.1%
    Fiscal year ending Dec 31, 2027$12.30$11.74$11.88$11.97$12.17+1.0%
    Quarter ending Mar 31, 2027$2.73$2.74$2.65$2.65$2.65+2.9%

    Frequently Asked Questions About NBIX

    What is the NBIX stock forecast?

    Consensus analyst estimates put Neurocrine Biosciences's EPS at $10.59 for the fiscal year ending Dec 31, 2026, on revenue of $3.99B. The consensus rating from 29 analysts is Buy.

    How do analysts rate NBIX stock?

    Of 29 analysts covering Neurocrine Biosciences, 4 rate it Strong Buy, 21 Buy, 4 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from NBIX next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $10.59, with estimates from $9.35 to $12.39 from 16 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $12.30, with estimates from $9.36 to $16.22 from 16 analysts.

    What revenue do analysts expect from Neurocrine Biosciences next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $3.99B, with estimates from $3.91B to $4.18B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $4.58B, with estimates from $4.37B to $5.07B.

    How many analysts cover NBIX?

    29 analysts rate Neurocrine Biosciences stock, and 16 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.